首页 > 最新文献

ESMO Open最新文献

英文 中文
34P DREAM: Data-driven drug repositioning through integrative analysis and machine learning 34P DREAM：通过综合分析和机器学习的数据驱动药物重新定位
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106138
S. De Summa , C. Saponaro , E. Mattioli , A. Zito , B. Pilato , G. Matera , M. Dioguardi , D. Monaco , S. Tommasi , M. Tritto , F. Buono , A. Rizzo
{"title":"34P DREAM: Data-driven drug repositioning through integrative analysis and machine learning","authors":"S. De Summa , C. Saponaro , E. Mattioli , A. Zito , B. Pilato , G. Matera , M. Dioguardi , D. Monaco , S. Tommasi , M. Tritto , F. Buono , A. Rizzo","doi":"10.1016/j.esmoop.2026.106138","DOIUrl":"10.1016/j.esmoop.2026.106138","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106138"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
48P CAF-specific targeting uncovered by patient-derived models synergistically restrains pancreatic tumor progression and chemoresistance 患者衍生模型揭示的48P caf特异性靶向协同抑制胰腺肿瘤进展和化疗耐药
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106153
Y. Oh , S. Chang
{"title":"48P CAF-specific targeting uncovered by patient-derived models synergistically restrains pancreatic tumor progression and chemoresistance","authors":"Y. Oh , S. Chang","doi":"10.1016/j.esmoop.2026.106153","DOIUrl":"10.1016/j.esmoop.2026.106153","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106153"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
5P Combination activity of T-DXd and dato-DXd with DNA damage response inhibitors 5P T-DXd和dato-DXd与DNA损伤反应抑制剂的结合活性
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106108
Y. Wallez , S. Agrawal , A. Nelson , L. Kazlauskas , S. Randle , M. Sung , A. Staniszewska , S. Cosulich , J. Nikkilä , J. Forment , E. Cadogan , M. Albertella , A. Lau , M.J. O'Connor , S. Gill , T. Proia , J. Mettetal
{"title":"5P Combination activity of T-DXd and dato-DXd with DNA damage response inhibitors","authors":"Y. Wallez , S. Agrawal , A. Nelson , L. Kazlauskas , S. Randle , M. Sung , A. Staniszewska , S. Cosulich , J. Nikkilä , J. Forment , E. Cadogan , M. Albertella , A. Lau , M.J. O'Connor , S. Gill , T. Proia , J. Mettetal","doi":"10.1016/j.esmoop.2026.106108","DOIUrl":"10.1016/j.esmoop.2026.106108","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106108"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
103P Novel covalent ligand modulates proteasome activity and assembly in colorectal cancer 新型共价配体调节大肠癌中蛋白酶体的活性和组装
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106245
Y.Y.H. Yip , T-Y. Koo , C.Y-S. Chung
{"title":"103P Novel covalent ligand modulates proteasome activity and assembly in colorectal cancer","authors":"Y.Y.H. Yip , T-Y. Koo , C.Y-S. Chung","doi":"10.1016/j.esmoop.2026.106245","DOIUrl":"10.1016/j.esmoop.2026.106245","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106245"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
78P Disproportionality analysis of triple M (3M) syndrome associated with PD-1 inhibitors 与PD-1抑制剂相关的三联M （3M）综合征的78P歧化分析
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106219
S.O. Abu Aleenein , M.M. Barbarawi , N.N. Al-Bzour , R.S. Malkawi , T.E. Alzaher
{"title":"78P Disproportionality analysis of triple M (3M) syndrome associated with PD-1 inhibitors","authors":"S.O. Abu Aleenein , M.M. Barbarawi , N.N. Al-Bzour , R.S. Malkawi , T.E. Alzaher","doi":"10.1016/j.esmoop.2026.106219","DOIUrl":"10.1016/j.esmoop.2026.106219","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106219"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESMO and ESMO Congress Officers ESMO和ESMO大会干事
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/S2059-7029(26)00858-6
{"title":"ESMO and ESMO Congress Officers","authors":"","doi":"10.1016/S2059-7029(26)00858-6","DOIUrl":"10.1016/S2059-7029(26)00858-6","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106916"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study☆ zanubrutinib + obinutuzumab与上次治疗复发/难治性滤泡性淋巴瘤的比较疗效：来自ROSEWOOD研究的生长调节指数分析。
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 Epub Date: 2026-03-31 DOI: 10.1016/j.esmoop.2026.106942
J. Trotman , K. Bouabdallah , F. Bijou , D. Šálek , A.C. de Oliveira , Y. Song , E.C. Kingsley , C.R. Flowers , S. Liao , S. Huang , N. Shah , L. Dumartin , P.L. Zinzani

Background

The phase II ROSEWOOD study (NCT03332017) compared zanubrutinib plus obinutuzumab (ZO) with obinutuzumab monotherapy (O) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who had received two or more prior lines of systemic therapy. Median progression-free survival (PFS) was longer with ZO versus O [28.0 versus 10.4 months; hazard ratio 0.50, 95% confidence interval (CI) 0.33-0.75].

Materials and methods

In this post hoc analysis, an intra-patient comparative analysis was carried out using the growth modulation index (GMI) to analyze the efficacy of ZO versus the last prior treatment received by patients in the ROSEWOOD study. A GMI of ≥1.33 was used as a threshold for significant clinical activity.

Results

In the overall population, median GMI was 2.7 (95% CI 1.6-4.9) in the ZO arm and 0.9 (95% CI 0.5-1.7) in the O arm. Analysis in subgroups of clinical interest in the ZO arm showed that PFS was longer with ZO than with the last prior treatment, and median GMI was ≥1.33 in all subgroups tested. Overall, PFS had improved (GMI ≥1.33) in >60% of patients with R/R FL who received ZO versus their last prior treatment.

Conclusions

This GMI analysis further supports the benefit of ZO as a novel therapeutic option for patients with R/R FL.
背景：II期ROSEWOOD研究（NCT03332017）比较了zanubrutinib + obinutuzumab （ZO）与obinutuzumab单药(O)治疗复发/难治性（R/R）滤泡性淋巴瘤（FL）患者，这些患者先前接受过两种或两种以上的全身治疗。ZO组的中位无进展生存期（PFS）比O组更长[28.0个月比10.4个月；风险比0.50,95%可信区间（CI） 0.33 ~ 0.75]。材料和方法：在这项事后分析中，使用生长调节指数（GMI）进行了患者内部比较分析，以分析ZO与ROSEWOOD研究中患者上次接受治疗的疗效。GMI≥1.33作为显著临床活动的阈值。结果：在总体人群中，ZO组的中位GMI为2.7 (95% CI 1.6-4.9)， O组的中位GMI为0.9 （95% CI 0.5-1.7）。对ZO组临床兴趣亚组的分析显示，ZO组的PFS比上次治疗组更长，所有亚组的中位GMI均≥1.33。总体而言，与上次治疗相比，接受ZO治疗的60%的R/R FL患者的PFS得到改善（GMI≥1.33）。结论：这项GMI分析进一步支持ZO作为R/R FL患者一种新的治疗选择的益处。
{"title":"Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study☆","authors":"J. Trotman ,&nbsp;K. Bouabdallah ,&nbsp;F. Bijou ,&nbsp;D. Šálek ,&nbsp;A.C. de Oliveira ,&nbsp;Y. Song ,&nbsp;E.C. Kingsley ,&nbsp;C.R. Flowers ,&nbsp;S. Liao ,&nbsp;S. Huang ,&nbsp;N. Shah ,&nbsp;L. Dumartin ,&nbsp;P.L. Zinzani","doi":"10.1016/j.esmoop.2026.106942","DOIUrl":"10.1016/j.esmoop.2026.106942","url":null,"abstract":"<div><h3>Background</h3><div>The phase II ROSEWOOD study (NCT03332017) compared zanubrutinib plus obinutuzumab (ZO) with obinutuzumab monotherapy (O) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who had received two or more prior lines of systemic therapy. Median progression-free survival (PFS) was longer with ZO versus O [28.0 versus 10.4 months; hazard ratio 0.50, 95% confidence interval (CI) 0.33-0.75].</div></div><div><h3>Materials and methods</h3><div>In this <em>post hoc</em> analysis, an intra-patient comparative analysis was carried out using the growth modulation index (GMI) to analyze the efficacy of ZO versus the last prior treatment received by patients in the ROSEWOOD study. A GMI of ≥1.33 was used as a threshold for significant clinical activity.</div></div><div><h3>Results</h3><div>In the overall population, median GMI was 2.7 (95% CI 1.6-4.9) in the ZO arm and 0.9 (95% CI 0.5-1.7) in the O arm. Analysis in subgroups of clinical interest in the ZO arm showed that PFS was longer with ZO than with the last prior treatment, and median GMI was ≥1.33 in all subgroups tested. Overall, PFS had improved (GMI ≥1.33) in &gt;60% of patients with R/R FL who received ZO versus their last prior treatment.</div></div><div><h3>Conclusions</h3><div>This GMI analysis further supports the benefit of ZO as a novel therapeutic option for patients with R/R FL.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106942"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
107P This abstract has been removed because it was not presented at the ESMO Targeted Anticancer Therapies Congress 2026 107P该摘要因未在2026年ESMO靶向抗癌治疗大会上提交而被删除
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.107705
{"title":"107P This abstract has been removed because it was not presented at the ESMO Targeted Anticancer Therapies Congress 2026","authors":"","doi":"10.1016/j.esmoop.2026.107705","DOIUrl":"10.1016/j.esmoop.2026.107705","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 107705"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
72P Selecting the right partner: How chemotherapy backbone shapes outcomes of anti–PD-(L)1 in first-line TNBC 选择合适的合作伙伴：化疗支柱如何影响一线TNBC抗pd -(L)1的结果
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106213
L. Sisca , M.G. Polito , A. Cortellini , B. Vincenzi , G. Tonini , F. Pantano
{"title":"72P Selecting the right partner: How chemotherapy backbone shapes outcomes of anti–PD-(L)1 in first-line TNBC","authors":"L. Sisca ,&nbsp;M.G. Polito ,&nbsp;A. Cortellini ,&nbsp;B. Vincenzi ,&nbsp;G. Tonini ,&nbsp;F. Pantano","doi":"10.1016/j.esmoop.2026.106213","DOIUrl":"10.1016/j.esmoop.2026.106213","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106213"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
27eP Real-world efficacy and safety of trastuzumab emtansine (T-DM1 Biosimilar, Ujvira) in early and metastatic HER2-positive breast cancer: A multicentre pooled retrospective analysis from India 曲妥珠单抗emtansine （T-DM1生物仿制药，Ujvira）治疗早期和转移性her2阳性乳腺癌的实际疗效和安全性：一项来自印度的多中心汇总回顾性分析
IF 8.3 2区 医学 Q1 ONCOLOGY
ESMO Open
Pub Date : 2026-04-01 DOI: 10.1016/j.esmoop.2026.106130
S.S. Panda , A. Mahajan , L. Moharana , L. Samantaray , M. Chandrakanth , V. Agarwala , R. Manna , S.V. Saju , H.S. Raju , P. Ganesan , G. Shankar , A.O. Philips , S.L. Cyriac , A.K. Jose , U. P , K.B. Priya , A. Sehrawat , D. Sundriyal , H. Dhanai , B. Dubashi
{"title":"27eP Real-world efficacy and safety of trastuzumab emtansine (T-DM1 Biosimilar, Ujvira) in early and metastatic HER2-positive breast cancer: A multicentre pooled retrospective analysis from India","authors":"S.S. Panda ,&nbsp;A. Mahajan ,&nbsp;L. Moharana ,&nbsp;L. Samantaray ,&nbsp;M. Chandrakanth ,&nbsp;V. Agarwala ,&nbsp;R. Manna ,&nbsp;S.V. Saju ,&nbsp;H.S. Raju ,&nbsp;P. Ganesan ,&nbsp;G. Shankar ,&nbsp;A.O. Philips ,&nbsp;S.L. Cyriac ,&nbsp;A.K. Jose ,&nbsp;U. P ,&nbsp;K.B. Priya ,&nbsp;A. Sehrawat ,&nbsp;D. Sundriyal ,&nbsp;H. Dhanai ,&nbsp;B. Dubashi","doi":"10.1016/j.esmoop.2026.106130","DOIUrl":"10.1016/j.esmoop.2026.106130","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106130"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
ESMO Open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1